The long-term objectives of this project are 1) to systematically map the protein-protein interaction network mediated by modular domains (including their sequence specificity and in vivo interacting partners), 2) to understand the biological function of these interactions, and 3) to develop specific inhibitors against these domains as research tools and potential therapeutic agents. During this grant period, our studies will focus on 43 human Src homology 2 (SH2) domains. SH2 domains specifically function in protein tyrosine kinase pathways by binding to phosphotyrosyl (pY) proteins. SH2 domains perform a wide variety of functions and as such they are potential targets for therapeutic intervention of human diseases and conditions such as cancer, osteoporosis, allergy, asthma, and autoimmunity. The current grant period has the following specific aims.
Specific Aim 1 is to determine the """"""""high-resolution"""""""" sequence specificity for 20 or so SH2 domains that have been partially characterized by others and the structural basis for SH2 domains'ability to recognize multiple consensus sequences by a single binding site and their extended sequence specificity.
Specific Aim 2 is to determine the sequence specificity for 23 new SH2 domains involved in JAK/STAT signaling pathways.
Specific Aim 3 will employ a chemical/bioinformatic approach to identify the partner proteins for some of the SH2 domains. Finally in Specific Aim 4, linear and cyclic pY peptides and peptidyl aldehydes will be developed as specific SH2 domain inhibitors. The inhibitors will then be used to study the cellular function of the SH2 domain-containing proteins.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Synthetic and Biological Chemistry A Study Section (SBCA)
Program Officer
Fabian, Miles
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Schools of Medicine
United States
Zip Code
Rhodes, Curran A; Pei, Dehua (2017) Bicyclic Peptides as Next-Generation Therapeutics. Chemistry 23:12690-12703
Qian, Ziqing; Dougherty, Patrick G; Pei, Dehua (2017) Targeting intracellular protein-protein interactions with cell-permeable cyclic peptides. Curr Opin Chem Biol 38:80-86
Dougherty, Patrick G; Qian, Ziqing; Pei, Dehua (2017) Macrocycles as protein-protein interaction inhibitors. Biochem J 474:1109-1125
Upadhyaya, Punit; Bedewy, Walaa; Pei, Dehua (2016) Direct Inhibitors of Ras-Effector Protein Interactions. Mini Rev Med Chem 16:376-82
Trinh, Thi B; Upadhyaya, Punit; Qian, Ziqing et al. (2016) Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides. ACS Comb Sci 18:75-85
Trinh, Thi B; Pei, Dehua (2016) Screening One-Bead-One-Compound Peptide Libraries for Optimal Kinase Substrates. Methods Mol Biol 1360:169-81
Cheng, Ying; Chikwava, Kudakwashe; Wu, Chao et al. (2016) LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors. J Clin Invest 126:1267-81
Jiang, Bisheng; Pei, Dehua (2015) A Selective, Cell-Permeable Nonphosphorylated Bicyclic Peptidyl Inhibitor against Peptidyl-Prolyl Isomerase Pin1. J Med Chem 58:6306-12
Qian, Ziqing; Upadhyaya, Punit; Pei, Dehua (2015) Synthesis and screening of one-bead-one-compound cyclic peptide libraries. Methods Mol Biol 1248:39-53
Qian, Ziqing; Dougherty, Patrick G; Pei, Dehua (2015) Monitoring the cytosolic entry of cell-penetrating peptides using a pH-sensitive fluorophore. Chem Commun (Camb) 51:2162-5

Showing the most recent 10 out of 66 publications